- Home
- NMIH vs AKRO Comparison
NMIH vs AKRO Comparison
Compare NMIH & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMIH
- AKRO
- Stock Information
- Founded
- NMIH 2011
- AKRO 2017
- Country
- NMIH United States
- AKRO United States
- Employees
- NMIH N/A
- AKRO N/A
- Industry
- NMIH Property-Casualty Insurers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- NMIH Finance
- AKRO Health Care
- Exchange
- NMIH Nasdaq
- AKRO Nasdaq
- Market Cap
- NMIH 2.8B
- AKRO 2.8B
- IPO Year
- NMIH 2013
- AKRO 2019
- Fundamental
- Price
- NMIH $37.88
- AKRO $39.85
- Analyst Decision
- NMIH Buy
- AKRO Strong Buy
- Analyst Count
- NMIH 7
- AKRO 9
- Target Price
- NMIH $42.14
- AKRO $76.29
- AVG Volume (30 Days)
- NMIH 850.3K
- AKRO 1.1M
- Earning Date
- NMIH 04-29-2025
- AKRO 05-16-2025
- Dividend Yield
- NMIH N/A
- AKRO N/A
- EPS Growth
- NMIH 14.57
- AKRO N/A
- EPS
- NMIH 4.63
- AKRO N/A
- Revenue
- NMIH $667,964,000.00
- AKRO N/A
- Revenue This Year
- NMIH N/A
- AKRO N/A
- Revenue Next Year
- NMIH $5.10
- AKRO N/A
- P/E Ratio
- NMIH $8.18
- AKRO N/A
- Revenue Growth
- NMIH 11.61
- AKRO N/A
- 52 Week Low
- NMIH $31.59
- AKRO $17.86
- 52 Week High
- NMIH $42.49
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- NMIH 65.10
- AKRO 44.56
- Support Level
- NMIH $37.19
- AKRO $41.60
- Resistance Level
- NMIH $38.97
- AKRO $46.47
- Average True Range (ATR)
- NMIH 0.88
- AKRO 2.26
- MACD
- NMIH 0.49
- AKRO 0.08
- Stochastic Oscillator
- NMIH 81.47
- AKRO 21.84
About NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.